|
Multicenter Phase II/III Study of Oxaliplatin Plus Cyclophosphamide (C) [OXC] Versus Cisplatin (P) Plus Cyclophosphamide [CPC] in Advanced Chemonaive Ovarian Cancer (AOC) Patients (Pts): Final Results. |
|
|
Consulting or Advisory Role - Lilly; Pfizer |
Research Funding - Amgen; Bayer; Boehringer Ingelheim; Genentech; Lilly; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Genentech; Neon Therapeutics |
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst) |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Elan |
|
|
Honoraria - Amgen; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD Oncology; Roche/Genentech; Sanofi |
Research Funding - Janssen-Cilag (Inst); Lilly (Inst); Merck Serono (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Sanofi |